COMMUNIQUÉS West-GlobeNewswire

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026
09/06/2026
BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present [...]
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
09/06/2026
Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study in Third Quarter of [...]
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
09/06/2026
Discussion explores challenges of immunologically “cold” tumors and the potential for scalable engineered cell therapies to expand patient access in oncology Access the segment here CAMBRIDGE, Mass., June 09, 2026 ( [...]
MindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection Kiosks
09/06/2026
VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “ Company ” or “ MindBio ”), a biotechnology company commercializing AI-driven [...]
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
09/06/2026
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal [...]
CVRx Announces Chief Financial Officer Transition
09/06/2026
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
09/06/2026
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific [...]
Transactions in connection with share buy-back program
09/06/2026
Company announcement no. 20 - 26 9 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Philips Future Health Index 2026: AI is already saving clinicians time and delivering measurable impact in healthcare
09/06/2026
June 9, 2026 AI saves clinicians the equivalent of 16 working days a year, with half saying it has increased their capacity to see patients 39% say AI has identified or helped prevent potential medical errors at least [...]
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
09/06/2026
PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potential of delivering a first-in-class precision medicine treatment in DED This FDA-aligned trial targets the specific [...]
AscellaHealth Establishes International Strategic Advisory Council, Enhances Global Life Sciences Support Services Amid Regulatory and Market Complexity
09/06/2026
DUBLIN and BERWYN, Pa., June 09, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the formation of its [...]
Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme
09/06/2026
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease Two-year programme expands Harness' [...]
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
09/06/2026
Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, [...]
FloBiotech Announces Agreement with UCLA Health® to Advance Neurodegenerative Disease Therapeutics
09/06/2026
BASEL, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- FloBiotech today announced an agreement with UCLA Health to advance a novel class of therapeutics targeting biologically validated protective pathways in [...]
Rapid Nutrition Featured on CNBC Discussing Key Trends Shaping the Future of Consumer Wellness
09/06/2026
CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving consumer wellness landscape LONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext [...]
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
08/06/2026
Penny Carlson will oversee global clinical development operations across Kymera’s oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE [...]
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
08/06/2026
ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and [...]
Tango Therapeutics Announces Proposed $500 Million Public Offering
08/06/2026
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer [...]
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
08/06/2026
Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical [...]

Pages